Research Reports | Market Assessment
October 2021

PD-L1 – Epidemiology – Mature Markets

Clarivate Epidemiology has created a robust repository of the prevalence of biomarker- and mutation-defined treatment-eligible cancer populations. Using Clarivate’s Biomarker Epidemiology, you can now save months of time and resources researching individual tumors in which a biomarker may be significant by quickly accessing data on the size of biomarker patient populations, based on diverse eligibility criteria and treatment settings.

In addition to an extensive literature review and modeling, we leverage our in-house estimates of cancer incidence for solid and hematological malignancies. All estimates are rigorously researched and transparently reported.

PD-L1 Epidemiology enables you to:

  • Complete PD-L1-driven market-sizing assessments based on the size of patient populations and patient flows.
  • Build the foundation of a market forecast for strategic planning for PD-L1-targeting for new and existing assets.
  • Understand how the patient populations for PD-L1 will evolve over time.
  • Answer any question you may have about specific subpopulations, PD-L1, and the impact of new studies.

ADDITIONAL CAPABILITIES

  • Patient-flow diagrams.
  • Customizable populations and data visualization dashboards.
  • Testing rates and companion diagnostic information.
  • Real-world data augmentation.
  • Patient journey and demographic characteristics.
  • Real-world analysis of associated comorbidities and treatments.

Table of contents

  • PD-L1 - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
        • Key Updates
      • Diagnosed Incidence of Cancers with PD-L1 Expression per 100,000 People of All Ages in 2021 and 2031
      • Analysis of the Diagnosed Incidence of Cancers with PD-L1 Expression in 2021 by Cancer Site
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases with PD-L1 Expression
      • Diagnosed NSCLC Incident Cases with PD-L1 Expression using 22C3 antibody at TPS>=1%
      • Diagnosed NSCLC Incident Cases with High PD-L1 Expression using 22C3 antibody at TPS>=50%
      • Diagnosed Gastric Adenocarcinoma Incident Cases with PD-L1 Expression using 22C3 antibody at CPS>=1
      • Diagnosed Urothelial Carcinoma Incident Cases with PD-L1 Expression using 22C3 antibody at CPS>=10
      • Diagnosed Urothelial Carcinoma Incident Cases with PD-L1 Expression using SP142 antibody at IC>=5%
      • Diagnosed Triple Negative Breast Cancer Incident Cases with PD-L1 Expression using SP142 antibody at IC>=1%
      • Diagnosed Triple Negative Breast Cancer Incident Cases with PD-L1 Expression using 22C3 antibody at CPS>=10
      • Diagnosed Cervical Cancer Incident Cases with PD-L1 Expression using 22C3 antibody at CPS>=1
      • Diagnosed SCCHN- Larynx Cancer Incident Cases with PD-L1 Expression using 22C3 antibody at CPS>=1
      • Diagnosed SCCHN- Hypopharynx Cancer Incident Cases with PD-L1 Expression using 22C3 antibody at CPS>=1
      • Diagnosed SCCHN- Oropharynx Cancer Incident Cases with PD-L1 Expression using 28-8 antibody at TC>=1%
      • Diagnosed First-Line Drug-Treatable Population with PD-L1 Expression
      • Diagnosed NSCLC First-Line Drug-Treatable Population with PD-L1 Expression using 22C3 antibody at TPS>=1%
      • Diagnosed NSCLC First-Line Drug-Treatable Population with PD-L1 Expression using 22C3 antibody at TPS>=50%
      • Diagnosed Gastric Adenocarcinoma First-Line Drug-Treatable Population with PD-L1 Expression using 22C3 antibody at CPS>=1
      • Diagnosed Urothelial Carcinoma First-Line Drug-Treatable Population with PD-L1 Expression using 22C3 antibody at CPS>=10
      • Diagnosed Urothelial Carcinoma First-Line Drug-Treatable Population with PD-L1 Expression using SP142 antibody at IC>=5%
      • Diagnosed Triple Negative Breast Cancer First-Line Drug-Treatable Population with PD-L1 Expression using SP142 antibody at IC>=1%
      • Diagnosed Triple Negative Breast Cancer First-Line Drug-Treatable Population with PD-L1 Expression using 22C3 antibody at CPS>=10
      • Diagnosed Cervical Cancer First-Line Drug-Treatable Population with PD-L1 Expression using 22C3 antibody at CPS>=1
      • Diagnosed SCCHN- Larynx Cancer First-Line Drug-Treatable Population with PD-L1 Expression using 22C3 antibody at CPS>=1
      • Diagnosed SCCHN- Hypopharynx Cancer First-Line Drug-Treatable Population with PD-L1 Expression using 22C3 antibody at CPS>=1
      • Diagnosed SCCHN- Oropharynx Cancer First-Line Drug Treatable Population with PD-L1 Expression using 28-8 antibody at TC>=1%
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Diagnosed Incident Cases
        • Studies Excluded in the Analysis of Diagnosed Incident Cases
      • Risk/Protective Factors
        • Bibliography
        • Abbreviations
        • Glossary
    Login to access report
    Back to all Market Assessment reports
    Login to access report

    launch Related Market Assessment Reports